semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-65.0,  Adult Lymphoblastic Lymphoma Disease ALL in complete remission (CR) at the time of transplant. Remission is defined as "less than 5.0% bone marrow lymphoblasts by morphology," as determined by a bone marrow aspirate obtained within 2 weeks of study registration Philadelphia chromosome positive ALL is allowed Lymphoid blastic crisis of CML will be included (provided that patients achieve CR) Age Equal or above age 40 and up to 65 years. If younger than 40, there must be comorbidities which preclude the patient to undergo CyTBI conditioning regimen Organ Function All organ function testing should be done within 28 days of study registration Cardiac: Left ventricular ejection fraction (LVEF) ≥ 50% by MUGA (Multi Gated Acquisition) scan or echocardiogram Pulmonary: FEV1 (Forced expiratory volume in 1 second) and FVC (Forced vital capacity) ≥ 50% predicted, DLCO (alveolar diffusion capacity for carbon monoxide) (corrected for hemoglobin) ≥ 50% of predicted Renal: The estimated creatinine clearance (CrCl) must be equal or greater than 60 mL/min/1.73 m2 as calculated by the Cockcroft-Gault Formula: CrCl = (140-age) x weight (kg) x 0.85 (if female)/72 x serum creatinine (mg/dL) Hepatic  Non-compliant to medications No appropriate caregivers identified HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive Active life-threatening cancer requiring treatment other than ALL Uncontrolled medical or psychiatric disorders Uncontrolled infections, defined as positive blood cultures within 72 hours of study entry, or evidence of progressive infection by imaging studies such as chest CT scan within 14 days of registration Active central nervous system (CNS) leukemia Preceding allogeneic HSCT Receiving intensive chemotherapy within 21 days of registration. Maintenance type of chemotherapy will be allowed
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Nos Metastatic Recurrent Women Aged 18 years and over With an invasive breast cancer diagnosed by cytology or histology Tumors cT0 to cT3, CN0-3 No clinical evidence of metastasis at the time of Untreated including scored for breast cancer surgery in progress Patient receiving a social security system Patient mastering the French language Free and informed consent for additional biological samples, different questionnaires and collecting information on resource usage  Metastatic breast cancer Local recurrence of breast cancer History of cancer within 5 years prior to entry into the trial other than basal cell skin or carcinoma in situ of the cervix Already received treatment for breast cancer ongoing Blood transfusion performed for less than six months Persons deprived of liberty or under supervision (including guardianship)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thyroid Cancer Newly diagnosed with a first occurrence of thyroid cancer <2-4 weeks of diagnosis (i.e., histologically confirmed thyroid cancer (papillary, follicular, or medullary type; TNM classification system) Willing to participate in the EG meetings >18 years Alert and capable of giving free and informed consent Able to speak and read English or French  Anaplastic thyroid cancer Karnofsky Performance Status (KPS) score <60 (rated by the Research Coordinator (RC) or referring physician) or expected survival <6 months according to clinical judgment
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Chronic Pain Women Clinical diagnosis of chronic pelvic pain More than eighteen years Non-menstrual or noncyclic pelvic pain Duration of pain of at least 6 months  Duration of pain less than 6 months Women who were pregnant in the last 12 months
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Lymphoma ≥60 years of age Histological confirmed DLBCL/follicular lymphoma grade IIIb by WHO classification, with any IPI (International Prognostic Index) Newly diagnosed, with no previous treatment Non-localised stage, i.e. lymphoma that does not fit into a single radiotherapy field (including clinical stage IA with large tumour mass until stage IV) with at least one measurable lesion ECOG performance status 0 to 2 Present appropriate haematologic, liver (ALT or AST < 2.5 ULN ? upper limit of normal) and renal functions (creatinine < 2.5 ULN) , unless changes are secondary to lymphoma LVEF at rest ? 55%, with no documented history of congestive heart failure (CHF), serious arrhythmia or acute myocardial infarction  Clinical stage I without large tumour mass or clinical stage IIA with fewer than three affected areas (stage-IIB patients are considered suitable, regardless of the number of affected areas) CNS infiltration Transformed lymphoma, although with no previous treatment, as well as other histological subtypes such as mantle cell lymphoma, peripheral T-cell lymphoma and its variants and post-transplant lymphoproliferative syndrome Clinically significant secondary cardiovascular disease Signs of any severe, acute or chronic and active infection Concurrent malignancy or history of other neoplasia except basal cell carcinoma (BCC) and cervical or breast carcinoma in situ (CIN) Patients with positive results in the HBV, HIV or HCV RNA tests Any previous treatment for DLBCL/follicular lymphoma grade IIIb
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Breast Neoplasms Clinical status of lymph nodes must be available Sonographical status of lymph nodes must be available Patients must consent to documentation of cancer treatment Histologic diagnosis of invasive breast cancer, clinical stage T1-4, M0 (non-inflammatory T4c) Patients scheduled for neoadjuvant chemotherapy Treatment with a 3-weekly FEC or AC regimen (3-4 cycles) followed by 3-4 cycles of q3 weekly docetaxel or paclitaxel Local HER2 status of tumor biopsy must be negative  The patient has a prior history of invasive or metastatic breast cancer The patient had prior excisional biopsy of the primary invasive breast cancer The patient had prior ipsilateral sentinel axillary lymph node biopsy for breast cancer The patient cannot safely or feasibly undergo biopsy of the primary tumor The patient has a diagnosis of Stage IV (distant metastatic) breast cancer The patient has proven HER2-positive breast cancer, defined as a pathology report of amplification of the gene or 3+ score for immunohistochemical staining
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Ovarian Epithelial Cancer Carcinoma in Situ Ovarian Cancer BRCA1/2 mutation carriers strong family history of breast and/or ovarian cancer suggestive for a germ line mutation in a relevant gene  pregnant incapacitated persons
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Breast Cancer Breast cancer patients eligible for sentinel node dissection Invasive ductal or invasive lobular carcinoma Ductal carcinoma in situ undergoing total mastectomy Clinically node-negative 100 years  Inflammatory breast cancer Pregnant or lactating Preoperative chemotherapy Prior axillary ultrasound guided core needle biopsy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HER2-positive Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Pathologically confirmed diagnosis of breast cancer (central confirmation is not required) Patients must be at least 18 years of age Metastatic or advanced breast cancer that is evaluable OR metastatic or advanced breast cancer that is measurable for response as per Response Evaluation in Solid Tumors (RECIST) 1.1 Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Life expectancy of at least 3 months as assessed by the investigator Patients with estrogen receptor (ER)+ breast cancer must have received prior treatment with at least one hormone therapy Absolute neutrophil count ≥ 1,500 cells/uL Platelets ≥ 100,000/uL Hemoglobin ≥ 9.0g/dL Total bilirubin ≤ 1.5 x the upper limit of normal (ULN)  Fewer than 21 days since last anti-tumor therapy, including chemotherapy, biologic except trastuzumab, experimental, immune, radiotherapy for the treatment of breast cancer, with the following exceptions Hormone therapy Palliative radiation therapy involving =< 25% of marrow-bearing bone is allowed if completed within >= 14 days prior to first study treatment Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable/evaluable disease Major surgery within 4 weeks prior to first dose of ganetespib Poor venous access for study drug administration Study drug administration via indwelling catheters is allowed only if the catheter is made of silicone material No prior chemotherapy in the metastatic setting is allowed Prior pertuzumab is not allowed in the metastatic setting. Pertuzumab given in the neoadjuvant and/or adjuvant setting is allowed History of intolerance or hypersensitivity to trastuzumab and/or pertuzumab
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female gender Age ≥18 years Performance Status Eastern Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer Primary tumor greater than 1 cm diameter, measured by clinical examination and mammography or ultrasound Any N No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed) Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization Known hormone receptor status  Previous (less than 5 years) or current history of malignant neoplasms, except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study Preexisting peripheral neuropathy ≥ grade 2 Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (≥180/110), unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety Unresolved or unstable, serious adverse events from prior administration of another investigational drug Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of ICF Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies) Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Breast Cancer Histologically confirmed stage I-III breast carcinoma 2. <65 years old 3. Female 4. Scheduled to receive chemotherapy containing doxorubicin/cyclophosphamide once every 3 weeks for 4 cycles and weekly paclitaxel for 12 cycles starting in either the adjuvant or neoadjuvant setting 5. May receive adjuvant endocrine therapy subsequently (endocrine therapy can be either tamoxifen or aromatase inhibitors) for Healthy Controls Each subject must meet the following to be enrolled in this study. 1. <65 years old 2. Female  Previous exposure to chemotherapy/anti-hormonal therapy for any other malignancy 2. Concomitant second primary in-situ or invasive carcinoma or previous history of carcinoma/carcinoma-in-situ 3. Known disease or injury to the central nervous system (including neurodegenerative diseases, epilepsy), severe visual or auditory disorders 4. Motor weakness due to any cause which makes using a touchscreen computer difficult 5. Known background of depression, anxiety disorders or other neurobehavioural conditions 6. Previous history of cognitive impairment 7. Ongoing use of tranquilisers or anti-depressants 8. Previous neuropsychological testing 9. Current or previous history of alcohol or drug dependence for Healthy Controls Subjects who meet any of the following will be excluded from the study. 1. Previous exposure to chemotherapy/anti-hormonal therapy for any other malignancy 2. Concomitant second primary in-situ or invasive carcinoma or previous history of carcinoma/carcinoma-in-situ 3. Known disease or injury to the central nervous system (including neurodegenerative diseases, epilepsy), severe visual or auditory disorders 4. Motor weakness due to any cause which makes using a touchscreen computer difficult 5. Known background of depression, anxiety disorders or other neurobehavioural conditions 6. Previous history of cognitive impairment 7. Ongoing use of tranquilisers or anti-depressants 8. Previous neuropsychological testing 9. Current or previous history of alcohol or drug dependence
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Glioblastoma single enhancing lesion of the brain with MRI appearance consistent with GBM Must be appropriate for Gliadel® wafer implant Pathologic confirmation of GBM no gross residual tumor found on the immediate postoperative MRI scan Volumetric measurements of the resection cavity margin being < 50 cc Karnofsky performance status (KPS) 80% or better Must be able to undergo MRI imaging with gadolinium Willingness to have follow up visits at Barrow Neurological Institute(BNI)  multi-focal tumors tumors which extend across the corpus callosum residual nodular disease Tumors, with a contraindication to Gliadel® implant, such as an anticipated extensive ventricular opening resulting from complete resection Tumor measuring greater than 50cc in volume (on post-operative scan) Volume < 50 cc if volume if a significant volume of eloquent tissue is included in the proposed treatment volume Unable to undergo MRI with gadolinium History of cancer within 2 years of GBM diagnosis (basal and squamous cell skin cancers are allowed) Patient is not willing to follow up at BNI
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Breast Cancer Written informed consent for all study procedures according to local regulatory requirements prior to enrollment into the study. 2. Age ≥ 18 years. 3. Histologically proven metastatic or locally recurrent invasive breast cancer. 4. Tumor tissue (FFPE and frozen) from recurrent or metastatic lesions available for research purposes  Eastern Cooperative Oncology Group (ECOG) Performance Status >2. 2. The biopsy procedure is estimated to be too risky for the patient. 3. Any bevacizumab treatment administered less than 3 weeks before new biopsy procedure. 4. No appropriate wash-out period for patients on anticoagulation therapy